Search

Your search keyword '"Lise Tarnow"' showing total 347 results

Search Constraints

Start Over You searched for: Author "Lise Tarnow" Remove constraint Author: "Lise Tarnow"
347 results on '"Lise Tarnow"'

Search Results

251. 19. Efficacy and Safety of Liraglutide Added to Insulin in Type 1 Diabetes: The LIRA-1 Trial (277-OR)

252. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

253. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy

254. Analysis of 14 candidate genes for diabetic nephropathy on chromosome 3q in European populations: strongest evidence for association with a variant in the promoter region of the adiponectin gene

255. The xylosyltransferase I gene polymorphism c.343GT (p.A125S) is a risk factor for diabetic nephropathy in type 1 diabetes

256. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy

257. Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?

258. Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy

259. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy

260. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes

261. Impact of polymorphisms in the genes encoding xylosyltransferase I and a homologue in type 1 diabetic patients with and without nephropathy

262. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study

265. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications

266. Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients

267. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy

268. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study

269. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes

270. 40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

271. Association between mannose-binding lectin and vascular complications in type 1 diabetes

272. Progression of nephropathy in type 2 diabetic patients

273. Low Birth Weight: A Risk Factor for Development of Diabetic Nephropathy?

274. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes

275. Birth weight--a risk factor for progression in diabetic nephropathy?

276. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

278. Role of Plasma Homocysteine and Plasminogen Activator Inhibitor-1 in the Progression of Diabetic Nephropathy

279. Preventing diabetic nephropathy: an audit

280. Remission of nephrotic-range albuminuria in type 1 diabetic patients

281. Progression of diabetic nephropathy

282. An Orally Administered Ghrelin Agonist (TZP-102) Decreases the Overall Severity of Symptoms of Diabetic Gastroparesis (GP): Phase 2 Proof of Concept Study - Preliminary Results

283. SERUM PLACENTAL GROWTH FACTOR (PLGF) PREDICTS ALL-CAUSE AND CARDIOVASCULAR MORTALITY BUT NOT DETERIORATION OF KIDNEY FUNCTION IN TYPE 1 DIABETIC PATIENTS WITH DIABETIC NEPHROPATHY: PP.6.254

284. Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus

285. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

286. The Trp64Arg amino acid polymorphism of the beta3-adrenergic receptor gene does not contribute to the genetic susceptibility of diabetic microvascular complications in Caucasian type 1 diabetic patients

287. Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy

288. Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy

289. Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy

290. Amadori albumin in type 1 diabetic patients: Correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries

291. Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients

292. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment

293. The prevalence of coeliac disease in adult Danish patients with type 1 diabetes with and without nephropathy

294. Mo2090 Gastric Emptying, Glycemia, and Upper GI Symptoms Are Independent Factors in Diabetic Gastroparesis

295. Influence of Erythropoietin on Cognitive Performance during Experimental Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Randomized Cross-Over Trial

296. Genetics of diabetic nephropathy

297. Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy

298. Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies

299. 54 EFFECT OF ONE YEAR TREATMENT WITH INSULIN AND ORAL GLUCOSE-LOWERING AGENTS ON LIPID LEVELS IN NON-OBESE PATIENTS WITH TYPE 2-DIABETES

300. TZP-102, Ghrelin Agonist Phase 2 Data: The Improvement in Symptoms of Gastroparesis (Nausea, Early Satiety, Bloating and Abdominal Pain) Significantly Correlated With Patient Rating of Overall Treatment Effect

Catalog

Books, media, physical & digital resources